Trial Profile

An Open-Label, One Treatment, Four Group, Parallel Group Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entrectinib (Primary)
Indications Acute myeloid leukaemia; Brain metastases; Malignant melanoma; Non-small cell lung cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Roche

22 Nov 2021 Status changed from active, no longer recruiting to completed.
13 Sep 2021 Planned End Date changed from 2 Sep 2021 to 16 Sep 2021.
13 Sep 2021 Planned primary completion date changed from 2 Sep 2021 to 16 Sep 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com